Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Market Cap	$1.62B	P/E Ratio	N/A
52W High	$48.26	52W Low	$1.87
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	20.3%	52W Position	79.0%
Overall Score	55	Value Score	50
Quality Score	52	Technical Score	63

EPS Current Est	$-1.07	EPS Next Est	$-1.25
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TERN	$38.52	+4.62%	3.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TERN	$38.52	+4.6%	3.63M
3
4
5
6

TERN

TERN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Terns Pharmaceuticals Inc. Data in Excel

Get Terns Pharmaceuticals Inc. Data in Excel